Search
Hengrui Pharmaceutical's proprietary Class 1 new drug, eltrombopag ethanolamine tablets, has received approval for its drug marketing authorization application from China's National Medical Products Administration. This innovative medication is indicated for use in adult and pediatric patients aged 6 years and older who suffer from persistent and chronic primary immune thrombocytopenia (ITP) and have previously exhibited inadequate responses to treatments such as glucocorticoids, immunoglobulins, and others. Eltrombopag ethanolamine tablets function as an oral non-peptide thrombopoietin receptor (TPO-R) agonist, effectively stimulating platelet production. Prior to this latest approval, the drug was authorized in June 2021 for the treatment of adult patients with chronic ITP and adult patients with severe aplastic anemia.
-
C114 Communication Network -
Communication Home
